Literature DB >> 23510229

OPPIDUM surveillance program: 20 years of information on drug abuse in France.

Elisabeth Frauger1, Christophe Moracchini, Reynald Le Boisselier, David Braunstein, Xavier Thirion, Joëlle Micallef.   

Abstract

It is important to assess drug abuse liability in 'real life' using different surveillance systems. Some are based on specific population surveys, such as individuals with drug abuse or dependence, or under opiate maintenance treatment, because this population is very familiar with drugs and is more likely to divert or abuse them. In France, an original surveillance system based on this specific population and called 'Observation of illegal drugs and misuse of psychotropic medications (OPPIDUM) survey' was set up in 1990 as the first of its kind. The aim of this article is to describe this precursor of French drug abuse surveillance using different examples, to demonstrate its ability to effectively give health authorities and physicians interesting data on drug abuse. OPPIDUM is an annual, cross-sectional survey that anonymously collects information on abuse and dependence observed in patients recruited in specialized care centers dedicated to drug dependence. From 1990 to 2010, a total of 50,734 patients were included with descriptions of 102,631 psychoactive substance consumptions. These data have outlined emergent behaviors such as the misuse of buprenorphine by intravenous or nasal administration. It has contributed to assess abuse liability of emergent drugs such as clonazepam or methylphenidate. This surveillance system was also able to detect the decrease of flunitrazepam abuse following implementation of regulatory measures. OPPIDUM's twenty years of experience clearly demonstrate that collection of valid and useful data on drug abuse is possible and can provide helpful information for physicians and health authorities.
© 2013 The Authors Fundamental and Clinical Pharmacology © 2013 Société Française de Pharmacologie et de Thérapeutique.

Entities:  

Keywords:  pharmacoepidemiology; postmarketing surveillance system; prescription drug abuse; substance-related disorders

Mesh:

Substances:

Year:  2013        PMID: 23510229     DOI: 10.1111/fcp.12024

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  7 in total

1.  Detection of signals of abuse and dependence applying disproportionality analysis.

Authors:  V Pauly; M Lapeyre-Mestre; D Braunstein; M Rueter; X Thirion; E Jouanjus; J Micallef
Journal:  Eur J Clin Pharmacol       Date:  2014-11-20       Impact factor: 2.953

2.  Identification of Somatic Disorders Related to Psychoactive Drug Use from an Inpatient Database in a French University Hospital.

Authors:  Margaux Lafaurie; Liselotte Pochard; Clémence Lotiron; Laurent Molinier; Maryse Lapeyre-Mestre; Emilie Jouanjus
Journal:  Clin Drug Investig       Date:  2018-10       Impact factor: 2.859

3.  Sensitized nucleus accumbens dopamine terminal responses to methylphenidate and dopamine transporter releasers after intermittent-access self-administration.

Authors:  Erin S Calipari; Sara R Jones
Journal:  Neuropharmacology       Date:  2014-03-13       Impact factor: 5.250

Review 4.  A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world.

Authors:  Michelle R Lofwall; Sharon L Walsh
Journal:  J Addict Med       Date:  2014 Sep-Oct       Impact factor: 3.702

5.  Increase of high-risk tramadol use and harmful consequences in France from 2013 to 2018: Evidence from the triangulation of addictovigilance data.

Authors:  Anne Roussin; Thomas Soeiro; Charlotte Fouque; Emilie Jouanjus; Elisabeth Frauger; Nathalie Fouilhé; Michel Mallaret; Joëlle Micallef; Maryse Lapeyre-Mestre
Journal:  Br J Clin Pharmacol       Date:  2022-04-05       Impact factor: 3.716

Review 6.  Early Detection of Prescription Drug Abuse Using Doctor Shopping Monitoring From Claims Databases: Illustration From the Experience of the French Addictovigilance Network.

Authors:  Thomas Soeiro; Clémence Lacroix; Vincent Pradel; Maryse Lapeyre-Mestre; Joëlle Micallef
Journal:  Front Psychiatry       Date:  2021-05-17       Impact factor: 4.157

7.  Methylphenidate amplifies the potency and reinforcing effects of amphetamines by increasing dopamine transporter expression.

Authors:  Erin S Calipari; Mark J Ferris; Ali Salahpour; Marc G Caron; Sara R Jones
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.